In the second of a two-part series, leaders of industry associations present their expectations for pharmacy operators for this year. 2023 was a pivotal year for health policy, to say the least.
In the second of a two-part series, leaders of industry associations present their expectations for pharmacy operators for this year.
In the second of a two-part series, leaders of industry associations present their expectations for pharmacy operators for this year. Former Defense Secretary Donald Rumsfeld once observed that “there are known knowns. There are things we know we know. We also know there are known unknowns.
In the second of a two-part series, leaders of industry associations present their expectations for pharmacy operators for this year. The past year was significant for the pharmaceutical industry, as we witnessed major milestones and celebrated advancements in innovation.
In the first of a two-part series, leaders of industry associations present their expectations for pharmacy operators for this year. The views of other organizations will appear in the next issue of Chain Drug Review. Specialty pharmacy continues to be dynamic, demanding and disruptive.
In the first of a two-part series, leaders of industry associations present their expectations for pharmacy operators for this year. The views of other organizations will appear in the next issue of Chain Drug Review. 2023 was a momentous year for community pharmacy in Canada.
In the first of a two-part series, leaders of industry associations present their expectations for pharmacy operators for this year. The views of other organizations will appear in the next issue of Chain Drug Review. The date January 1 can have varying meanings for people.
In the first of a two-part series, leaders of industry associations present their expectations for pharmacy operators for this year.
In the first of a two-part series, leaders of industry associations present their expectations for pharmacy operators for this year. The views of other organizations will appear in the next issue of Chain Drug Review.
In the first of a two-part series, leaders of industry associations present their expectations for pharmacy operators for this year. The views of other organizations will appear in the next issue of Chain Drug Review.
In the first of a two-part series, leaders of industry associations present their expectations for pharmacy operators for this year.
As the start of a new year approaches, long-standing trends are raising the stakes for big pharmacy operators and other companies with the ambition to re-engineer a health care system plagued by chronic issues of access, quality and cost.
This is an especially special holiday season for participants in and advocates of chain drug retailing in America. Reason? The season celebrates and pauses to recall the 90th anniversary of the National Association of Chain Drug Stores.
Retail pharmacy has taken a beating in the press recently. Mainstream media outlets, including The New York Times, The Washington Post, CBS News and PBS, covered labor actions undertaken by pharmacists motivated by concerns about working conditions and potential risks to patients.
and there remain many who fondly recall a simpler time in chain drug retailing — must surely have a second thought or two about Rite Aid, in the wake of that venerable retailer’s fight for survival. Once upon a not-so-distant time, Rite Aid, along
